

# International Cancer Cluster Showcase 2015

Monday, June 15th, 2015

Philadelphia Convention Center – Rooms 111 and 112

Kindly sponsored by:



11:30 – 12:30 p.m. **REGISTRATION AND LIGHT LUNCH with POSTER SESSION**

12:30 – 12:45 p.m. **Opening and Welcome**  
ICCS Organizing Partners and Sponsors

12:45 – 1:05 p.m. **Québec, Canada**  
Exactis  
IRICoR  
Kanyr Pharma

1:05 – 1:25 p.m. **Oslo Cancer Cluster, Norway**  
Inven2  
Ultimovacs  
Nordic Nanovector

1:25 – 1:45 p.m. **Massachusetts Technology Transfer Center, USA**  
Cyta Therapeutics  
Eutropics  
Cellanyx Diagnostics

1:45 – 2:05 p.m. **Wistar Institute and Partners, Philadelphia, USA**  
Keosys  
Immunacel  
BioDetego

2:05 – 2:35 p.m. **Networking Break & Poster Session**

2:35 – 3:00 p.m. **Cancer-Bio-Santé and Cancer Campus, France**  
GamaMabs Pharma  
Toulouse Tech Transfer  
PepTherapy  
XenTech

3:00 – 3:20 p.m. **Chicago Cancer Cluster, USA**  
NanoCytomics  
Actuate Therapeutics, Inc.  
UChicagoTech

3:20 – 3:40 p.m. **OBN, United Kingdom**  
PsiOxus Therapeutics  
Magnus Life  
Inflection Biosciences

3:40 – 3:45 p.m. **Closing Remarks**

3:45 – 4:45 p.m. **Networking Reception and Poster Session**

For more information please visit: [www.internationalcancercluster.org](http://www.internationalcancercluster.org)



E X A C T I S



OSLO CANCER CLUSTER



Cancer-Bio-Santé

CLUSTER



# International Cancer Cluster Showcase 2015 – Presenting companies

**Actuate Therapeutics, Inc.** is a private biopharmaceutical company developing novel therapeutics that target Glycogen Synthase Kinase-3 $\beta$  (GSK-3 $\beta$ ). Our focus is on the development of compounds for combination use in high impact carcinomas including glioblastoma, ovarian, breast, and pancreatic cancers. In addition, we are advancing research for the development of our compounds for the treatment of neurodegenerative diseases, including Alzheimer's, bipolar disorder, and schizophrenia, where early studies are yielding promising results. Currently, Actuate Therapeutics has pharmacology and toxicology studies underway to optimize the formulation and dosing regimen of our lead drug candidate prior to human testing. These studies will be used to support a human trial planned for initiation in early 2017.

**Contact:** Daniel M. Schmitt, President and CEO; T: +1 847-986-4190; [dschmitt@actuatetherapeutics.com](mailto:dschmitt@actuatetherapeutics.com)  
[www.actuatetherapeutics.com](http://www.actuatetherapeutics.com)

**ACTUATE**  
THERAPEUTICS

**BioDetego** is developing the next generation of cancer diagnostics. Supported by compelling clinical data in multiple cancer types, our diagnostic platform, VASPfore, determines a person's risk of developing metastasis and need for chemotherapy. Our lead test, VASPfore-CRC, is poised to change the standard of care in colorectal cancer diagnosis and treatment. The test will:

- Accurately determine individual risk of metastasis and chemotherapy need
- Provide 100% actionable information to reduce harmful under- and overtreatment
- Change treatment decisions and improve health outcomes
- Deliver enormous savings by reducing payor costs

**Contact:** David S. Zuzga, Ph.D., CEO; T: +1 856-701-2453; [zuzga@biodetego.com](mailto:zuzga@biodetego.com)  
[www.biodetego.com](http://www.biodetego.com)

**BIODETEGO**  
life revealed

**Cellanix** Diagnostics is developing a proprietary living cell phenotypic cancer diagnostic platform to aid clinical decision making. The company's unique 'biopsy-on-a-chip' methodology provides quantitative, actionable assessments of individual cancer cells in biopsy samples using multiple phenotypic biochemical and biophysical markers of tumor aggressiveness and metastatic potential. Cellanix has demonstrated clinical proof-of-concept with its lead product in development, a diagnostic to improve risk stratification in men with low and intermediate grade prostate cancer and thereby reduce overtreatment.

**Contact:** Ashok C. Chander, PhD, CEO; T: +1 571.212.9991; [ashok@cellanix.com](mailto:ashok@cellanix.com)  
[www.cellanix.com](http://www.cellanix.com)

**CELLANYX**  
DIAGNOSTICS

**Cyta Therapeutics, Inc.** (Cyta) is a next generation nanomedicines company developing breakthrough targeted therapies based on the patented novel chemistry-based designed nanogels invented by polymer chemist, Professor Thayumanavan at University of Massachusetts, Amherst. Cyta's nanogels will improve therapeutic benefit with reduced side effects for patients by tightly encapsulating and protecting drugs during the journey to the targeted site of disease and utilizing a unique intracellular trigger to release the drug payload within the diseased cell.

**Contact:** Bonnie Fendrock, CEO and Co-founder; T: +1 617-947-1416; [bonnie.fendrock@cytatx.com](mailto:bonnie.fendrock@cytatx.com)

**CYTA**  
THERAPEUTICS

**Eutropics** is advancing personalized medicine by providing novel, predictive diagnostic tests that are uniquely accurate in guiding patient cancer treatments. The Eutropics PraediCare Dx™ assay provides novel functional data from cancer cells and has been validated as a clinical diagnostic test in hematologic oncology. The platform provides a novel, in vitro method to identify when cancer patients are most likely to respond to certain therapies. Distinct readouts from testing biopsied patient samples prior to initiation of treatment will be used to provide the physician with actionable data for guiding the use of available treatment options. Partnerships are in place to bring the test to clinical use as a CDx and to move the platform forward for use as a stand-alone clinical Dx.

**Contact:** Michael H. Cardone, Ph.D., Co-founder, President & CEO; T: +1 617-803-1511;  
[mcardone@Eutropics.com](mailto:mcardone@Eutropics.com); [www.eutropics.com](http://www.eutropics.com)

**eutropics**  
guiding cancer treatment

**Exactis Innovation** is a non-profit organization with the vision to improve cancer survivorship through innovative research. Our mission is to become a leading international network of excellence for next generation biomarker-led translational and clinical research that will accelerate drug development, increase treatment options for cancer patients and achieve cost-savings to the healthcare system.

**Contact:** Thérèse Gagnon-Kugler, PhD, CEO; T: +1 418 781-0500, ext 102; [tgagnon-kugler@exactis.ca](mailto:tgagnon-kugler@exactis.ca)

**EXACTIS**

# International Cancer Cluster Showcase 2015 – Presenting companies

**GamaMabs Pharma** is a private French biopharmaceutical company dedicated to the development of original optimized monoclonal antibodies which activate immune cells in cancer. Gamamabs' lead program is 3C23K, in late pre-IND stage, which binds to AMHR11, an unaddressed target specifically expressed in gynecological cancers. 3C23K displays a high efficacy in relevant patho-mimetic in vivo models, and has demonstrated a particularly safe profile in regulatory preclinical studies. The main objective of GamaMabs is to develop its pipeline up to Proof of Concept in patients.

**Contact:** M. Stephane Degove, CEO; T: +33 5 31 61 60 69; [sdegove@gamamabs.com](mailto:sdegove@gamamabs.com)  
[www.gamamabs.com](http://www.gamamabs.com)



**IMMUNACCEL** is a unique and value-add platform for cancer immunotherapy companies. Our 3-D cancer-immune cell organotypic culture system is a physiologically relevant culture system utilizing primary human cancer cells and cytotoxic T cells (CTL) generated from patient T-cells, amongst fibroblasts and collagen assembled in a 3-D organotypic model. Our system was originally designed to understand the biology of tumor infiltrating lymphocytes (TILs) in the evaluation of biological therapeutics and small molecule inhibitors of chemokines and their receptors. We provide services to functionally validate existing pipeline candidates identify and validate new therapeutic candidates that can drive or inhibit activity of T-lymphocytes, and discover useful companion diagnostics to steer clinical development of said candidates

**Contact:** Vik Subbu, COO; T: +1 240-994-1132; [vik.subbu@immunaccel.com](mailto:vik.subbu@immunaccel.com)  
[www.immunaccel.com](http://www.immunaccel.com)



**Inflection Biosciences Ltd** - based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments were licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises IBL-202 (PIM/PI3K inhibitor) and IBL-301 (PIM/PI3K/mTOR inhibitor), selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (highly selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of hematological malignancies and treatment resistant solid tumors. Inflection Biosciences was named 'Start-up Company of the Year' at the 2014 Irish Pharma Awards.

**Contact:** Darren Cunningham, CEO; T: +353 1400 3615; [dcunningham@inflectionbio.com](mailto:dcunningham@inflectionbio.com)  
[www.inflectionbio.com](http://www.inflectionbio.com)



**Inven2** is the largest technology transfer office in the Nordic region and a leading actor within Life Science. Inven2 commercializes research from the Oslo University Hospital, Scandinavia's largest hospital and responsible for approximately 50 percent of all medical and healthcare research conducted in Norway. These research environments are pioneers within several areas of immunology and cell based cancer therapies. Inven2 has started over 43 companies and has increased its number of successful commercialization with 35 percent for the second consecutive year. Inven2 has developed a large portfolio with several ongoing innovation projects within immuno-oncology therapies and methods.

**Contact:** Ole Kristian Hjelstuen, CEO; T: + 47 908 24 724; [o.k.hjelstuen@inven2.com](mailto:o.k.hjelstuen@inven2.com)  
[www.inven2.com](http://www.inven2.com)



**IRICoR**, the Institute for Research in Immunology and Cancer—Commercialization of Research, is a not-for-profit drug discovery and commercialization center created in 2008 and based at Université de Montréal (UdeM). IRICoR is a fully-integrated center under a single roof, with one of the largest academia-based industry-experienced medicinal chemistry groups in Canada. Our mission is to rapidly translate highly innovative and commercially promising projects from IRIC/UdeM/collaborating centers into high value novel therapies mainly in oncology and immunology. We support and invest in selected projects to rapidly transition them from academia to the market with the best targeted partners for development and financing.

**Contact:** Nadine Beauger, VP Scientific Liaison; T: +1 514-343-6111 ext. 0315; [nadine.beauger@iricor.ca](mailto:nadine.beauger@iricor.ca)  
[www.iricor.ca](http://www.iricor.ca)



# International Cancer Cluster Showcase 2015 – Presenting companies



**Kanyr Pharma** - A Montreal-based company with more than 15 years' experience in both drug discovery and biological investigation of the protein tyrosine phosphatases (PTPs). Kanyr has developed Immunyr™, a novel immunotherapy technology that could provide a major improvement in the function of all dendritic cell-based therapeutic vaccines. Immunyr™ includes a proprietary PTP inhibitor which, when added to dendritic cells, greatly enhances their activity prior to reinjection into the patient. Importantly, it has the potential to work synergistically with most existing immune and conventional targeted therapies. Kanyr is currently seeking a development partner to initiate a clinical trial in pancreatic cancer.

**Contact:** Daniel Bouthillier, President and CEO; T: +1 514-402-1764; [daniel.bouthillier@kaneq.ca](mailto:daniel.bouthillier@kaneq.ca)  
[www.kaneq.com](http://www.kaneq.com)



**KEOSYS Medical Imaging** is a software editor provider composed of experts in telecommunication, IT and medical imaging. KEOSYS offers innovative medical imaging solutions for clinical routine (radiology/Nuclear Medicine) & clinical research.

**Contact:** Paul POMMEL, Clinical Trial Project Manager; T: +1-855-553-6797; [paul.pommel@keosys.com](mailto:paul.pommel@keosys.com)  
[www.keosys.com](http://www.keosys.com)



**Magnus Life Science** is a company based on ground-breaking clinical and academic research some of which originated from University College London, one of the world's leading universities. Magnus Life Science has a unique model with projects established as separate companies with founding scientists as shareholders. The Company is developing treatments for a range of diseases based on a core understanding of blood flow. Magnus has secured £15.5m in private equity funding. Two programs are further supported by €11.5m in EC FP7 grants. Magnus Life is our oncology program, which is pursuing a new approach to the treatment of solid tumors. This involves studying the interplay between the immune system and growth factors released by the tumor and identifies targets that can 'uncloak' the tumor to allow immune system attack. With a state-of-the-art small molecule discovery approach, we are identifying novel therapeutics with potential oral bioavailability to target melanoma and other solid tumors.

**Contact:** Mark Lees, Director Portfolio Management; T: +44 (0) 20 3282 7567;  
[mlees@magnuslifescience.co.uk](mailto:mlees@magnuslifescience.co.uk)  
[www.magnuslifescience.com](http://www.magnuslifescience.com)



**NanoCytomics** is a medical diagnostics company developing low cost, minimally invasive, highly sensitive test that can be performed in the primary care setting to screen patients for the risk of developing lung and colon cancer. NanoCytomics envisions that their developed test will enable identifying patients with early stage cancer in turn leading to an improvement in the cancer survival rates.

**Contact:** Dimitra Georganopoulou, Ph.D., Innovation and Commercialization Officer; T: +1 847-467-3095;  
[d-georganopoulou@northwestern.edu](mailto:d-georganopoulou@northwestern.edu)  
[www.nano-cytomics.com](http://www.nano-cytomics.com)



**Nordic Nanovector** is focusing on the development and commercialization of novel targeted therapeutics for hematological cancers. The Company's lead clinical-stage product opportunity is Betalutin™, the first in a new class of Antibody-Radionuclide-Conjugates (ARCs), designed to improve upon and complement current options for the treatment of Non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities. Nordic Nanovector was established in 2009, leveraging expertise in targeted cancer therapy from the Norwegian Radium Hospital. The company has its main office and laboratories in Oslo, Norway with subsidiaries in Switzerland and the UK.

**Contact:** Jan A. Alfheim, Chief Operating Officer; T: +47 46 44 00 45; [jalfheim@nordicnanovector.com](mailto:jalfheim@nordicnanovector.com)  
[www.nordicnanovector.com](http://www.nordicnanovector.com)

# International Cancer Cluster Showcase 2015 – Presenting companies

**Pep Therapy** is a biotech company, which develops targeted therapies for cancers with high medical needs. PEP-Therapy operates a Cell Penetrating & Interfering Peptide technology (CP&IP) for the development of therapeutic products. These innovative molecules penetrate cells and block relevant protein-protein interactions, thus specifically inhibiting key pathological mechanisms, avoiding side effect. DPT-C9h is PEP-Therapy's first CP&IP product and a novel, targeted approach to cancer therapy. DPT-C9h specifically blocks the Caspase9/PP2A interaction,



- triggering apoptosis in cancer cells without harm to healthy cells,
  - while leaving the other signaling pathways intact, limiting the risk of side effects.
- DPT-C9h has demonstrated proof of concept in patient-derived xenograft (PDX) models, in uveal melanoma, breast, ovary and lung primary tumors.

**Contact:** Antoine Prestat, CEO; T: +33 144 278 190; [contact@pep-therapy.com](mailto:contact@pep-therapy.com)  
[www.pep-therapy.com](http://www.pep-therapy.com)

**Psioxus Therapeutics Ltd** is a private Oxford, UK development stage biotechnology company developing novel therapeutics in the field of Cancer. Our lead program, MT-102, is an Anabolic Catabolic Transforming Agent (ACTA) which has completed phase II development and will enter phase III in 2015. Our second development program, enadenotucirev (formerly ColoAd1), is a systemically delivered oncolytic virus. Enadenotucirev is in phase I/II clinical development for colorectal, ovarian, bladder, renal and non-small cell lung cancer. Arming enadenotucirev with antibody constructs (including aPD1, aPDL1 and aCTLA4) is a platform technology with extensive pre-clinical data.



**Contact:** Hooshmand Sheshbaradaran, CBO; T: +44 1235 835328; [hooshmand@psioxus.com](mailto:hooshmand@psioxus.com)  
[www.psioxus.com](http://www.psioxus.com)

**Toulouse Tech Transfer (TTT)** is a technology transfer company. The core business of TTT is to invest in technology maturing programs based on public research results, which covers:

- IP (Intellectual Property) and legal issues, in order to create more value through patents and know-how;
- Marketing to identify which products should be addressed and for which market;
- Technical operations to design and finance relevant proof of concept and/or prototype to trigger industrial interest for the technology.

TTT also supports startup creation. The leverage provided by TTT is reducing SMB cash burning for the riskiest phase of innovation. France now counts 14 technology transfer companies as TTT, called SATTs.

**Contact:** Jean-Pierre Saintouil, Director Health Division, Head of Innovation; T: +336 87 61 83 12; [saintouil@toulouse-tech-transfer.com](mailto:saintouil@toulouse-tech-transfer.com)  
[www.toulouse-tech-transfer.com](http://www.toulouse-tech-transfer.com)

**UChicagoTech**, the Center for Technology Development & Ventures, transforms University discoveries into products, services, and ventures. UChicagoTech's oncology portfolio includes immuno-oncology therapies, novel targeted therapeutics, and diagnostic platforms. One of our leading technologies, Affinity Clamps, is a diagnostic platform that delivers proteins tailor designed to recognize and bind to epitopes. The University of Chicago Medicine Comprehensive Cancer Center (UCCCC) supports a translational and interdisciplinary research program to prevent and reduce the devastating effects of cancer. UCCCC efforts have resulted in groundbreaking technologies for cancer treatment. The Genomic Data Commons at UChicago's Center for Data Intensive Science is a collaboration with the National Cancer Institute to create a comprehensive computational facility for cancer genomics data.

**Contact:** Thelma Tennant, PhD, Project Manager; T: +1 773-834-4020; [ttennant@tech.uchicago.edu](mailto:ttennant@tech.uchicago.edu)  
<http://tech.uchicago.edu/>



# International Cancer Cluster Showcase 2015 – Presenting companies

**Ultimovacs** (est. 2011) is developing a therapeutic cancer vaccine (TCV) directed against human telomerase (hTERT). UV1 is a synthetic peptide vaccine. The vaccine is a result of many years of pre-clinical and clinical research at the Norwegian Radium Hospital. The peptides included in the vaccine have been identified through observation of patients with advanced disease surviving > 10years after vaccination with an hTERT TCV. Ultimovacs is performing three clinical trials. Two trials are documenting safety and the vaccines ability to activate the T-cells against cancer cells expressing the vaccine hTERT fragments. A third clinical trial is assessing safety and clinical outcomes when combining UV1 with ipilimumab in patients with malignant melanoma. Preliminary results from the clinical trials show a good safety profile and that approx. 80% of the patients get T-cells activated against the vaccine peptides.

**Contact:** Øyvind Kongstun Arnesen, CEO; T: + 47 90 97 12 26; [oyvind.arnesen@ultimovacs.com](mailto:oyvind.arnesen@ultimovacs.com)  
[www.ultimovacs.com](http://www.ultimovacs.com)

**XenTech** is a science-driven company dedicated to preclinical evaluation of anticancer therapies and biomarker discovery. Our full-service preclinical research organization serves small to big biopharmaceutical companies since 2006. XenTech is the pioneer in the Patient-Derived tumor Xenograft technology, with a staff's preclinical experience of more than 1400 studies.

Our methodology takes into account the following key issues:

- Enhance your value creation with reliable preclinical data available to potential partners,
- Understand patient segmentation relevant to your compounds,
- Design a tailored approach to address your specific needs

XenTech has a large panel of primary tumor xenografts models, among which the world's most characterized panel of breast cancer PDX. XenTech biomarker discovery programs started in 2009 led to the discovery of 3 companion diagnostic signatures.

**Contact:** Pascal LEURAUD, PhD., Chief Operating Officer; T: +33 1 60 87 89 21; [Pascal.Leuraud@xentech.eu](mailto:Pascal.Leuraud@xentech.eu)  
[www.xentech.eu](http://www.xentech.eu)

## Poster partner

**Cancer Campus** is the Paris biocluster dedicated to cancer innovation and a prime location for biotechs to develop their disruptive innovative therapies. On a site housing one of the largest European comprehensive cancer center (Gustave Roussy), Cancer Campus is based on a top-level research and training entity, working in synergy with innovative companies with the objective of accelerating therapeutic innovation. Cancer Campus is supported by a non-profit organization whose members are Gustave Roussy, the Assistance Publique-Hôpitaux de Paris, the Paris-Sud University, the local authorities and the Paris Chamber of Commerce, in partnership with the Medicen competitiveness cluster.

**Contact:** Valerie Helin, [Valerie.HELIN@cancer-campus.com](mailto:Valerie.HELIN@cancer-campus.com); <http://www.cancer-campus.com/en/accueil>

## Local partner

**The Wistar Institute** is the nation's first independent institution devoted to medical research and training. The Wistar Institute has evolved from its beginnings as an anatomical teaching museum to its present-day status as an international leader in basic biomedical research. In 1972, The Wistar Institute was designated a National Cancer Institute Cancer Center in basic research, a distinction it holds to this day.

Wistardiscoveries have led to the development of vaccines for rabies, rubella, and rotavirus, the identification of genes associated with breast, lung, and prostate cancer, and the development of monoclonal antibodies and other significant research technologies and tools.

**Contact:** Heather Steinman, [HSteinman@Wistar.org](mailto:HSteinman@Wistar.org); [www.wistar.org](http://www.wistar.org)

## Special thanks to our sponsors:

## Media Partner:



# International Cancer Cluster Showcase 2015 – Organizing partners

**Massachusetts Technology Transfer Center** - Massachusetts' unique ecosystem of leading research institutions, supporting organizations, and investor community spurs the creation of numerous new companies every year. Massachusetts' cancer expertise is maintained by cutting edge research at multiple institutions including the Dana-Farber Cancer Institute and the David Koch Institute for Integrative Cancer Research at MIT. Many of the newly formed companies in the Commonwealth focus on cancer diagnostics and treatment. The Massachusetts Technology Transfer Center is a non-profit organization that supports technology transfer activities from public and private research institutions to companies in Massachusetts. To achieve this goal, the Center works with technology transfer offices at Massachusetts research institutions; faculty, researchers, and students who have commercially promising ideas; and companies across the Commonwealth.

**Contact:** Abigail Barrow, [abarrow@umassp.edu](mailto:abarrow@umassp.edu); [www.mttc.org](http://www.mttc.org)

Identify the right patients for the right clinical trials! Our mission is to become a network of internationally renowned excellence in translational and clinical research based on new-generation biomarkers that contribute to the development of drugs, increase treatment options for cancer patients and thus achieve cost savings in the health care system. By building prospectively extremely basic clinical and molecular data of cancer patients, and across Canada, **Exactis** is able to rapidly identify patients for clinical trials based on biomarkers. The Center of Excellence in Innovation Exactis Precision Therapeutics is a non-profit organization. We believe in improving the chances of cancer survival through access to innovative personalized care.

**Contact:** Richard Cloutier, [Richard.cloutier@cqvb.gc.ca](mailto:Richard.cloutier@cqvb.gc.ca); [www.linkedin.com/company/exactis](http://www.linkedin.com/company/exactis)

The **Chicago Cancer Cluster** represents three outstanding cancer centers located in the City of Chicago. The centers are affiliated with the largest research institutions and the best medical facilities in Illinois, where they deliver high levels of care and treatment to over 17,000 new cancer cases per year, and provide access to a substantial network of clinical trial sites. More than 700 researchers investigate better treatments for patients through \$280+ million per year in grant funding, which has yielded promising new technologies available for license and several notable startup companies. Learn more about the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, the University of Chicago Comprehensive Cancer Center, and the University of Illinois Cancer Center.

**Contact:** [DVarshney@tech.uchicago.edu](mailto:DVarshney@tech.uchicago.edu)

**Oslo Cancer Cluster** is a research and industry cluster focused on oncology. Organized as non-profit member organization Oslo Cancer Cluster is dedicated to accelerate the development of new cancer treatments. The 70 members represent the entire R&D value chain and include academic research institutes, university hospitals, innovative SMEs and international Pharma companies. The cluster's growing pipeline comprises innovative therapeutics and diagnostics including several novel cancer immunotherapies in preclinical and clinical development.

**Contact:** Jutta Heix, [jh@oslocancercluster.no](mailto:jh@oslocancercluster.no); [www.oslocancercluster.no](http://www.oslocancercluster.no)

A unique and broad approach throughout the continuum of cancer **Cancer-Bio-Santé Cluster**, located in Toulouse, is the French cluster in France fully dedicated to the fight against Cancer, throughout a broad continuum approach involving prevention, diagnostics, therapeutics and patient monitoring. CBS supports companies from the Midi Pyrénées and Limousin regions, which develop innovative products in the fields of food & Health, Diagnostics, Biomarkers, Nanotechnologies, Medical Devices, Immunotherapy, Therapeutics, Biotechnologies and Telemedicine. The mission of the Cancer-Bio-Santé cluster is to support companies to develop innovative products by synergizing public and private research and clinical research actors.

**Contact:** Celine Bedja, [celine.bedja@cancerbiosante.fr](mailto:celine.bedja@cancerbiosante.fr); [www.cancerbiosante.fr](http://www.cancerbiosante.fr)

**OBN** is the Membership organization supporting and bringing together the UK's emerging life sciences companies, corporate partners and investors. Our 360-plus Member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland benefiting from our networking, partnering, purchasing, advising and advocacy activities.

**Contact:** [david.boal@obn.org.uk](mailto:david.boal@obn.org.uk); [www.obn.org.uk](http://www.obn.org.uk)

